Search - tctmd.com

Displaying 301 - 320 of 562

Sort: Relevancy | Date

Presentation TCT 2018

Mortality and Stroke Outcomes of PCI vs CABG in MVD and LMD With and Without Diabetes

Presenter: Antonio Colombo, Jeffrey W. Moses, Stuart J. Head

September 22, 2018

Presentation TCT 2018

Defining What Constitutes a Clinically Relevant Peri-Procedural MI: Analysis in > 17,000 Patients

Presenter: Antonio Colombo, Jeffrey W. Moses, Jung-Min Ahn

September 22, 2018

Presentation TCT 2018

PCI for Ischemia Part II: Why the ISCHEMIA Trial Might be Positive..or Negative!

Presenter: David J. Cohen, Sunil V. Rao, Ajay J. Kirtane

September 22, 2018

Presentation TCT 2018

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Presenter: David J. Cohen, Sunil V. Rao, Bernard J. Gersh

September 22, 2018

Presentation TCT 2018

Increasing Emphasis on QOL Outcomes: From Patient Preference to Instrument Validation

Presenter: David J. Cohen, Sunil V. Rao, John A. Spertus

September 22, 2018

Presentation TCT 2018

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Presenter: David J. Cohen, Sunil V. Rao, David J. Maron

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

Presentation TCT 2018

Ultra-Thin Strut DES: A Meaningful Advance?

Presenter: Renu Virmani, Clemens von Birgelen, Sripal Bangalore

September 22, 2018

Presentation TCT 2018

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Presenter: Renu Virmani, Clemens von Birgelen, David E. Kandzari

September 22, 2018

Presentation TCT 2018

Keynote: Why Do Contemporary DES Fail (Early and Late, Restenosis and Thrombosis)?

Presenter: Renu Virmani, Clemens von Birgelen, Michael Joner

September 22, 2018

Presentation TCT 2018

Debate: Drug-Coated Balloons Should be the Primary Treatment Strategy for Long-Segment SFA CTOs!

Presenter: Gary M. Ansel, Ehrin J. Armstrong, Carlos I. Mena-Hurtado

September 21, 2018

Presentation TCT 2018

Will Adjunctive Atherectomy Improve the Outcomes of Drug-Coated Balloons in Complex SFA Lesions?

Presenter: Gary M. Ansel, Ehrin J. Armstrong, Mehdi H. Shishehbor

September 21, 2018

Presentation ESC 2018

Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2

Presenter: Raban V. Jeger

August 31, 2018

News Conference News ESC 2018

BASKET-SMALL 2: Drug-Coated Balloon Fares Well Against DES for De Novo Small-Vessel Disease

Todd Neale

August 28, 2018

News Industry News

Medtronic Receives FDA Approval for 200mm & 250mm IN.PACT(TM) Admiral(TM) Drug Coated Balloons

June 18, 2018

Advertisement

Mortality and Stroke Outcomes of PCI vs CABG in MVD and LMD With and Without Diabetes

Defining What Constitutes a Clinically Relevant Peri-Procedural MI: Analysis in > 17,000 Patients

PCI for Ischemia Part II: Why the ISCHEMIA Trial Might be Positive..or Negative!

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Increasing Emphasis on QOL Outcomes: From Patient Preference to Instrument Validation

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Ultra-Thin Strut DES: A Meaningful Advance?

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Keynote: Why Do Contemporary DES Fail (Early and Late, Restenosis and Thrombosis)?

Debate: Drug-Coated Balloons Should be the Primary Treatment Strategy for Long-Segment SFA CTOs!

Will Adjunctive Atherectomy Improve the Outcomes of Drug-Coated Balloons in Complex SFA Lesions?

Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2

BASKET-SMALL 2: Drug-Coated Balloon Fares Well Against DES for De Novo Small-Vessel Disease

Medtronic Receives FDA Approval for 200mm & 250mm IN.PACT(TM) Admiral(TM) Drug Coated Balloons

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content